

# Relative Contribution of Pharmacokinetics and Immune Signatures to Clinical Outcomes in Patients With HIV-associated Cryptococcal Meningitis

Katharine E. Stott,<sup>1,2</sup> Dumizulu Tembo,<sup>2</sup> Cheusisime Kajanga,<sup>2</sup> Ajisa Ahmadu,<sup>2</sup> Dumisan Namakhwa,<sup>2</sup> Ruwanthi Kolamunnage-Dona,<sup>3</sup> Chandni Sarker,<sup>3,4</sup> Melanie Moyo,<sup>2,4,5</sup> Ebbie Gondwe,<sup>2</sup> Wezi Chimang'anga,<sup>2</sup> Madalitso Chasweka,<sup>2</sup> Reya V. Shah,<sup>5,6</sup> David S. Lawrence,<sup>6,7,8</sup> Thomas S. Harrison,<sup>5,9</sup> Joseph N. Jarvis,<sup>6,7</sup> David G. Lalloo,<sup>10</sup> William Hope,<sup>1,6</sup> and Henry C. Mwandumba<sup>2,6</sup>; The AMBITION Study Group<sup>a</sup>

<sup>1</sup>Antimicrobial Pharmacodynamics and Therapeutics group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK, <sup>2</sup>Mucosal and Vascular Immunology Group, Malawi Liverpool Wellcome Programme, Blantyre, Malawi, <sup>3</sup>Department of Health Data Science, University of Liverpool, Liverpool, UK, <sup>4</sup>Department of Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi, <sup>5</sup>Institute of Infection and Immunity, City St George's University London, London, UK, <sup>6</sup>Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Tropical Medicine, London, UK, <sup>7</sup>Botswana Harvard Health Partnership, Gaborone, Botswana, <sup>8</sup>School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, <sup>9</sup>MRC Centre for Medical Mycology, University Exeter, Exeter, UK, and <sup>10</sup>Liverpool School of Tropical Medicine, Liverpool, UK

**Background.** Host immune responses to HIV-associated cryptococcal meningitis are critical in disease outcome. Their interaction with antifungal drug exposure is poorly understood. This study explored associations between immune biomarkers, antifungal drug exposure, and clinical outcomes in HIV-associated cryptococcal meningitis.

**Methods.** We analyzed serial plasma and cerebrospinal fluid immune biomarkers from 64 participants recruited from the AMBITION-cm trial. We estimated individual-level exposure to amphotericin B, flucytosine, and fluconazole. Associations between immune biomarkers, pharmacokinetic parameters, and clinical outcomes were evaluated.

**Results.** An inflammatory cerebrospinal fluid response, characterized by coordination between tumor necrosis factor- $\alpha$ , granulocyte colony-stimulating factor, and interleukin-7 signaling, was linked to low fungal burden, low intracranial pressure, and survival. However, the value of specific immune biomarkers did not predict EFA or mortality. Exposure to amphotericin B was significantly associated with EFA.

**Conclusions.** Favorable clinical outcomes from HIV-associated cryptococcal meningitis are associated with coordinated inflammatory and cytotoxic responses in the central nervous system. Antifungal drug exposure was the dominant predictor of EFA.

**Keywords.** amphotericin B; cryptococcal meningitis; immunomodulation; pharmacodynamics; pharmacokinetics.

All-cause mortality from HIV-associated cryptococcal meningitis remains in the region of 25% to 36% at 10 weeks [1, 2]. The host immune response is central to the pathogenesis of cryptococcosis and determines whether infection is contained within pulmonary granulomas or becomes disseminated, including to the central nervous system (CNS) [3]. In advanced HIV, dysregulation of CD4+ T cells interferes with inflammatory signaling, enabling evasion of immune surveillance, persistence of infection, and CNS invasion [4, 5]. T-helper (Th) 1 inflammatory responses, including release of proinflammatory cytokines such as interferon-gamma (IFN- $\gamma$ ), tumor necrosis

factor-alpha (TNF- $\alpha$ ), interleukins (ILs)-2, 6, 8, and 17, are associated with enhanced early fungicidal activity (EFA) and reduced mortality [6–8]. This signalling promotes classical M1 macrophage polarization with attendant phagocytosis and fungicide [9, 10]. In mice, a predominance of CD4+ cells producing Th2-type responses with anti-inflammatory signaling and alternative (M2) macrophage activation is associated with detrimental outcomes [11, 12]—although this has not been consistently replicated in humans. Deficiency of Th1-type cytokines is associated with increased mortality in patients with cryptococcal meningitis [6, 13].

The relationships between T-cell responses, macrophage activation pathways, and clinical manifestations from cryptococcal infection are not straightforward. Additional complexity is added in the setting of antifungal therapy, which reduces fungal burden and impacts the associated immune response [14, 15]. In this study, we aimed to provide insight into the relative influence of the host response and antifungal drug exposure on clinical outcomes from HIV-associated cryptococcal meningitis. Immune biomarkers were measured in plasma and cerebrospinal fluid (CSF) collected serially from participants during the first 14 days of treatment. Posterior estimates of individual-level

Received 25 February 2025; editorial decision 21 March 2025; accepted 22 March 2025; published online 2 April 2025

<sup>a</sup>Study group members are listed in the acknowledgments.

Correspondence: Katharine E. Stott, PhD, Department of Pharmacology and Therapeutics, Antimicrobial Pharmacodynamics and Therapeutics group, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, Merseyside, UK (katstott@liverpool.ac.uk).

Open Forum Infectious Diseases®

© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

<https://doi.org/10.1093/ofid/ofaf190>

exposure to fluconazole, flucytosine, and amphotericin B were derived from population pharmacokinetic (PK) models. We examined the associations between immune biomarkers, antifungal drug exposure, and clinical outcomes from cryptococcal meningitis.

## MATERIALS AND METHODS

### Study Participants and Clinical Procedures

Participants were recruited from Queen Elizabeth Central Hospital in Blantyre, Malawi. People living with HIV with a confirmed first episode of cryptococcal meningitis were recruited as part of the phase III AMBITION-cm trial [1]. Participants were randomized 1:1 to receive induction therapy with either a single dose of liposomal amphotericin B (Ambisome, Gilead Sciences; 10 mg/kg/day) followed by 14 days of flucytosine (100 mg/kg/day) plus fluconazole (1200 mg/day)—the intervention arm—or 7 days of amphotericin B deoxycholate (1 mg/kg/day) plus flucytosine (100 mg/kg/day), followed by 7 days of fluconazole (1200 mg/day)—the control arm.

### Patient Consent Statement

All patients who had capacity provided written, informed consent for participation in the AMBITION-cm trial. If patients were incapacitated, consent was obtained from a next of kin with legal responsibility and then participants were re-consented if possible according to their clinical status. Ethical approval for AMBITION-cm was obtained from the Malawi National Health Sciences Research Committee (#1907) and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (#14355).

### Collection and Measurement of Soluble Biomarkers

Blood samples for measurement of immune biomarkers were collected on day 1 (before initiation of study drugs), day 7, and day 14. Blood samples for PK were collected on days 1 and 7 of the study at 0, 2, 4, 7, 12, and 23 hours after drug administration. CSF was obtained by lumbar puncture (LP) for measurement of immune biomarkers and PK before initiation of study drugs (day 1) and on days 7 and 14. Additional LPs were performed if clinically indicated for management of raised intracranial pressure. CSF obtained from those LPs was also analyzed.

Plasma and CSF samples were processed within 1 hour of collection. Samples were centrifuged at 3000 rpm (1500g) for 10 minutes at 4 °C before freezing at −80 °C until analysis on site at the Malawi Liverpool Wellcome Programme. We used the Luminex multianalyte platform (Luminex, Merck Millipore, Herts, UK) to measure IFN- $\gamma$ , TNF- $\alpha$ , granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-15, IL-17A, IL-12p40, IL-12p70, IL-1

receptor antagonist (IL-1ra), IFN- $\gamma$  inducible protein 10 (IP-10/CXCL10), vascular endothelial growth factor (VEGF)-A, monocyte chemoattractant protein 1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2), macrophage inflammatory protein (MIP)-1a/CCL3, MIP-1b/CCL4, and RANTES/CCL5, according to the manufacturer's instructions.

Quantitative cryptococcal culture was performed on days 1, 7, and 14 using serial dilutions of 100  $\mu$ L CSF with colony counting after 48 hours of growth at 30 °C. For this substudy, participants were followed up for 10 weeks with respect to mortality outcomes.

### Pharmacokinetic Analyses

The sampling, bioanalytical, and modeling techniques used for this study are explained in detail elsewhere [16–18]. In brief, concentration-time data for fluconazole, flucytosine, and amphotericin B in plasma (all drugs) and CSF (fluconazole and flucytosine only) were modeled using the nonparametric adaptive grid algorithm of the program Pmetrics [19] version 2.0.2 for R. Drug exposure was estimated by calculating the area under the concentration-time curve (AUC) using the Bayesian posterior PK predictions for each participant to perform trapezoidal approximation in Pmetrics. These same estimates of drug exposure were used by our group in another recent publication [18].

### Data Analysis

Two statistical techniques were employed to reduce the dimensionality of the large set of soluble biomarkers: principal component analysis (PCA) and network analysis. PCA derives linear functions (principal components [PCs]) that capture the variance in a dataset and that are unrelated to one another, increasing the interpretability of the data while minimizing information loss and avoiding multiple comparisons [20]. The purpose of performing PCA in this case was to reduce the “noise” created by relatively uninformative variables and to collapse variables that were correlated to one another, enabling simpler models of association between informative immune biomarkers, pharmacokinetic variables, and clinical outcomes. Network analysis places significance on the associations between variables, highlighting clusters of variables that are more closely related to one another than to other variables. The purpose of the network analyses performed here was to identify coordinated immune responses associated with clinical outcomes. The network analyses presented here included only those cytokines that were strongly correlated (Pearson's correlation coefficient,  $r$ ,  $\geq 0.70$ ;  $P < .05$ ).

Prior to PCA and network analysis, analyte concentrations were  $\log_{10}$  transformed and normalized to the mean value for that analyte across all timepoints. A “slope” value was calculated for each biomarker for each participant as a linear regression of the  $\log_{10}$  transformed, normalized concentration of that

biomarker over time. PCA and network analyses were performed on biomarker values from day 1 of the study and on the slope values.

Several clinical outcomes served as dependent variables: fungal burden at baseline prior to study drug administration, opening intracranial pressure at baseline, EFA (calculated as a linear regression of  $\log_{10}$  CFU/mL of CSF over the first 14 days of therapy) and mortality (followed up to 10 weeks). Regression models were used to examine the relationship between PCs, posterior PK predictions, and clinical outcome variables. Associations with opening pressure were adjusted for baseline fungal burden in CSF. Associations with EFA were adjusted for both baseline fungal burden and study arm. Associations with time to death were examined using Cox proportional hazards models and adjusted for baseline fungal burden because this is consistently associated with mortality from HIV-associated cryptococcal meningitis [21]. Interaction terms were included between each immune response PC and baseline fungal burden, to account for the presumed impact of the former on the latter. Statistical significance was defined as  $P < .05$ . Original data are available online within the [Supplementary material](#).

## RESULTS

### Participants

Between November 2018 and October 2019, 64 participants were recruited to this substudy of the AMBITION-cm trial—31 participants in the control arm and 33 in the single-dose liposomal amphotericin arm. The median age was 36 years (interquartile range [IQR] 33–41 years) and 37% of participants were female. Median weight was 50 kg (IQR 47–56 kg). Median CD4 cell count was 39 cells/mm<sup>3</sup> (IQR 21–83 cells/mm<sup>3</sup>,  $n = 57$ ). At the time of recruitment, 35 participants were taking antiretroviral treatment (ART) and 29 were not taking ART. The cumulative case fatality rate was 9% at 2 weeks (6/64) and 28% at 10 weeks (18/64).

### Plasma and CSF Immune Biomarkers

The range of biomarker concentrations at baseline (day 1) in plasma and CSF are shown in [Figure 1](#). The change in biomarker values over time is depicted in [Figure 2](#).

### Posterior Estimates of Drug Exposure

The final PK models revealed substantial interindividual variability in drug exposure in this critically unwell population. The median amphotericin B  $AUC_{0-24}$  in plasma was 0.028 g/L/h (IQR 0.014–0.540); flucytosine median  $AUC_{144-168}$  in CSF was 0.579 (IQR 0.343–0.813) and fluconazole median  $AUC_{144-168}$  was 5.504 (IQR 3.902–6.752). These time windows were chosen to capture the high peak plasma concentration of amphotericin B in the first 24 hours for those participants in the intervention arm and to capture steady state of flucytosine and fluconazole in the CNS.

### Principal Component Analysis

**Baseline Biomarker Values in Plasma and CSF.** PCA of plasma biomarkers from study day 1 demonstrated that 62.6% of the overall variance in the dataset was accounted for by a combination of PC1 (38.7%), PC2 (15.2%), and PC3 (8.7%). PC1 comprised a large group of cytokines that contributed relatively moderate, positive loading scores, implying that all variables contributed similar information to that PC. The variance in PC2 was primarily accounted for by negative loading scores for IL-12p70, IL-2, and VEGF, indicating that the absence of those variables contributed to PC2. PC3 was overwhelmingly described by a strong contribution from IL-17A, with moderate loading scores in other biomarkers ([Figure 3A](#)).


In CSF, 77.8% of the variance in the data from day 1 was accounted for by the combination of PC1 (57.0%), PC2 (12.3%), and PC3 (8.5%) ([Figure 3B](#)). A large group of biomarkers of Th1-, Th2-, and Th17-type responses drove the variance in PC1; the contribution of each of those biomarkers to PC1 was primarily positive and relatively homogeneous. The variance in PC2, in contrast, was chiefly accounted for by positive loading scores in a group of just 3 biomarkers: G-CSF, IL-7, and TNF- $\alpha$ . The chemokine RANTES was strongly negatively correlated with PC3.

**Dynamic Biomarker Values in Plasma and CSF.** Plasma biomarker concentrations were available for 39 participants on day 1, 41 on day 7, and 37 on day 14. In CSF, biomarker concentrations were available from 61 participants on day 1, 55 patients on day 7, and 53 participants on day 14.

In plasma, the first 3 PCs accounted for 67.5% of the variance in the dataset describing change in immune biomarkers over time: PC1 37.1%, PC2 21.6%, and PC3 8.8% ([Figure 3C](#)). In CSF, 66.6% of the total variance was accounted for by the first 3 PCs: PC1 45.0%, PC2 12.3%, and PC3 9.3% ([Figure 3D](#)). In both plasma and CSF, PC1 was again characterized by relatively homogeneous, moderately positive loading scores across all biomarkers, implying that all variables contributed similar information to that PC. In plasma, PC2 comprised negative loading scores for IL-2, IL-5, IL-12p40, IL-12p70, and IL-17A, indicating that the absence of those variables contributed to PC2. PC3 in plasma was dominated by a strong positive loading score for G-CSF (strong contribution to PC3) and a negative score in RANTES (absence of RANTES contributed to PC3). PC2 in the slope dataset from CSF values was characterized by relatively strong contributions from GM-CSF and RANTES, with a strong negative score for IL-2. PC3 comprised strong positive loading scores for G-CSF, IL-7, and TNF- $\alpha$ —the same biomarkers that presented the highest loading scores in the PCA of day 1 biomarkers in CSF.

### Network Analysis


**Baseline Biomarkers.** Network analysis of baseline plasma biomarkers suggested a particular pattern of biomarkers in participants with high fungal burden and those who died



**Figure 1.** Baseline immune biomarker concentrations. Baseline soluble biomarker concentrations in *A*, plasma and *B*, CSF in patients with HIV-associated cryptococcal meningitis. Boxes indicate median and interquartile range. Whiskers represent 10th and 90th percentiles. Abbreviation: CSF, cerebrospinal fluid.

before 10 weeks of follow-up (Figure 4). In these participants, there were 3 distinct clusters of immune biomarkers: (1) IL-17A, IL-12p40 and VEGF; (2) IL-5 and IL-12p70; and (3) all remaining biomarkers. Of note, the first of these distinct clusters (IL-17A, IL-12p40, and VEGF) was also seen in patients with high EFA, suggesting that this clustering alone was not

consistently related with either favorable or poor clinical outcomes. IL-17A, IL-12p40, and VEGF also clustered together in participants who were not taking ART, but not in those who were taking ART (Supplementary Figure 1). These are the same 3 biomarkers that contributed positive loading scores to PC3 in the PCA of baseline biomarker values in plasma.



**Figure 2.** Change in biomarker values over time in A) plasma and B) cerebrospinal fluid. Gray lines represent individual patient biomarker values over time; black line is the mean across the patient population.

Network analysis of day 1 CSF immune biomarker values revealed a more consistent pattern (Figure 5). In participants with favorable clinical outcomes (low baseline fungal burden, low opening pressure, fast EFA, and survival at 10 weeks) G-CSF, IL-7, and TNF- $\alpha$  clustered together, distinct from other biomarkers, indicating that these cytokines were more closely correlated to one another than they were to other biomarkers. This pattern was not present in participants with high baseline fungal burden, high CSF opening pressure, or in those who had died within 10 weeks of study enrolment. However, the same pattern was seen in participants with low EFA, suggesting that this clustering did not distinguish between patients with slow versus fast pharmacodynamic responses. In addition, the


pattern was present regardless of ART status. G-CSF, IL-7, and TNF- $\alpha$  are the same biomarkers that contributed strongly to PC2 in CSF.

#### Network Analysis

**Dynamic Biomarker.** Values Network analysis of the slope of each biomarker value revealed less consistent patterns than the networks of baseline biomarkers, in terms of associations with favorable versus poor clinical outcomes (Supplementary Figure 2). Overall, there was not a convincing trend in these analyses.

In CSF, the pattern of G-CSF, IL-7, and TNF- $\alpha$  clustering together, distinct from other biomarkers, was seen in biomarker





**Figure 2.** Continued


slope values (in keeping with the baseline dataset) in patients who survived to 10 weeks. This pattern was not observed in patients who were deceased at 10 weeks. In keeping with the baseline dataset, this clustering did not distinguish between patients with slow versus fast EFA ([Supplementary Figure 3](#)). There was no difference in the slope values of G-CSF, IL-7, or TNF- $\alpha$  between patients in the control versus single-dose arm of the study (data not shown).

#### Relationships Between Principal Components, Pharmacokinetic Variables and Clinical Outcomes

In regression models, we used the PCs from baseline data rather than the PCAs of slope values, since the PCA of baseline data identified the most consistent patterns.

There was a statistically significant association between PC3 in plasma and baseline fungal burden and between PC2 in CSF and baseline fungal burden ([Table 1](#)). Neither baseline fungal burden nor any of the PCs from plasma or CSF data were associated with lumbar opening pressure in univariate regression (data not shown) or multivariate regression ([Supplementary Table 1](#)).

Adjusting for baseline fungal burden and exposure to each antifungal drug, none of the immune data PCs was associated with EFA. However, both baseline fungal burden and exposure to amphotericin B were significantly associated with increased EFA: for each  $\log_{10}$  CFU/mL increase in fungal burden, EFA increased by 0.07  $\log_{10}$  CFU/mL/day (standard error 0.01,  $P < .001$ ); for each g/L/h increase in amphotericin B  $AUC_{0-24}$ , EFA increased by 0.14  $\log_{10}$  CFU/mL/day (standard error 0.04,  $P = .001$ ); [Table 2](#).



**Figure 3.** Principal component analysis. *A*, Plasma, day 1: PCs 1, 2, and 3 accounted for 38.7%, 15.2%, and 8.7% of the variance, respectively. The majority of soluble biomarkers in the dataset contribute relatively homogeneously to the variance in PC1. PC2 shows strongly negative loading scores in IL-12p70, IL-2, and VEGF, with PC3 predominated by a strongly positive loading score in IL-17A. *B*, CSF, day 1: PCs 1, 2, and 3 accounted for 57.0%, 12.3%, and 8.5% of the variance, respectively. Again, there is relatively homogeneous contribution to variance in PC1. In PC2 is overwhelmingly characterized by positive loadings in G-CSF, IL-7, and TNF- $\alpha$ . PC3, in contrast, is predominantly defined by a negative loading score in RANTES, as well as a moderately positive score in TNF- $\alpha$ . *C*, Plasma, slope values: PCs 1, 2, and 3 accounted for 37.1%, 21.6%, and 8.8% of the variance, respectively. PC1 was again characterized by relatively homogeneous, moderately positive loading scores across the majority of biomarkers. PC2 comprised negative loading scores in IL-2, IL-5, IL-12p40, and IL-12p70. PC3 was characterized by strong positive loading scores in the slope values for IL-6 and IL-7, and negative scores in the slope values for IP-10 and RANTES. *D*, CSF, slope values: PCs 1, 2, and 3 accounted for 45.0%, 12.3%, and 9.3% of the variance, respectively. PC1 was characterized by moderately positive loading scores across the majority of biomarkers. PC2 was characterized by relatively strong contributions from GM-CSF and RANTES, with a strong negative score for IL-2. PC3 comprised strong positive loading scores for G-CSF, IL-7, and TNF- $\alpha$ . Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; PC, principal component; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

A Cox proportional hazard model did not identify any statistically significant independent predictors of survival time among the PK parameters or PCs in univariate or multivariate analysis (data not shown).

## DISCUSSION

We present a comprehensive analysis of the immunophenotype both in the peripheral circulation and in the CNS of

patients with HIV-associated cryptococcal meningitis. There was a notable lack of dynamism in immune biomarker values over the first 14 days of treatment in either plasma or CSF, and analysis of the slope values of each biomarker did not yield significant information above that provided by analysis of baseline values. An explanation for this may be that the immune response to infection with *Cryptococcus* spp. is shaped prior to diagnosis and the initiation of antifungal therapy,





**Table 1. Adjusted Multivariable Regression Model Examining Predictors of Fungal Burden at Baseline**

|            | Regression Coefficient | Standard Error | P Value    |
|------------|------------------------|----------------|------------|
| Plasma PC1 | 0.25                   | 0.14           | .08        |
| Plasma PC2 | 0.12                   | 0.16           | .46        |
| Plasma PC3 | <b>0.44</b>            | <b>0.21</b>    | <b>.04</b> |
| CSF PC1    | −0.15                  | 0.10           | .15        |
| CSF PC2    | <b>−0.35</b>           | <b>0.17</b>    | <b>.04</b> |
| CSF PC3    | 0.21                   | 0.22           | .34        |

Bold values indicate statistically significant associations. Fungal burden measured in log<sub>10</sub> CFU/mL.

Abbreviations: CFU, colony forming unit; CSF, colony-stimulating factor; PC, principal component.

with fluctuations in responses relatively minor once disease is established.

In plasma, IL-12 p40, IL-17A, and VEGF contributed strongly to the PC that was statistically significantly associated with high baseline fungal burden—an established predictor of mortality in cryptococcal meningitis [18, 21, 22]. This was also reflected in the network analysis of plasma biomarkers at baseline. This combination of cytokines suggests Th1 and Th17 T-cell differentiation, neutrophil, and monocyte recruitment, activation of glial cells, and amplification of inflammatory signalling. Indeed, IL-12 is an essential cytokine for protective Th1 responses in murine models of cryptococcosis [23]. VEGF can additionally disrupt the blood–brain barrier to enable inflammatory cells and biomarkers to infiltrate the CNS. In contrast with other investigators [6], our data did not convincingly associate this pro-inflammatory signature in plasma with clinical benefit. This may be because the immune response in plasma does not reflect activity at the primary site of pathology in the CNS. Alternatively, it may be a function of the small number of participants in our cohort relative to the number of measured biomarkers.

In keeping with other cohorts, favorable clinical outcomes in our study were associated with a coordinated inflammatory and cytotoxic response in the CNS [6, 24]. TNF- $\alpha$  is a core Th1-type inflammatory and cytotoxic mediator, involved in protection against a range of intra- and extracellular pathogens [25–29]. TNF- $\alpha$  stimulates IFN- $\gamma$  production, the beneficial role of which is well documented in patients with HIV/CM [7, 30]. G-CSF promotes the differentiation of stem cells into cytotoxic neutrophils and monocytes [31, 32]. In vitro experiments suggest that G-CSF may also have direct immunomodulatory properties: the addition of G-CSF to neutrophils, monocytes, or monocyte-derived macrophages enhances cryptococcal killing both in the presence and absence of azole antifungal treatment [33]. IL-7 is essential for lymphopoiesis and plays a key role in homeostasis of T cells and inflammatory signalling networks [34–36]. There is evidence to suggest that amphotericin B has immunomodulatory effects and that these effects differ

**Table 2. Adjusted Multivariable Regression Model Examining Predictors of Early Fungicidal Activity**

|   | Regression Coefficient | Standard Error | P Value                    |
|---|------------------------|----------------|----------------------------|
| Baseline fungal burden (log <sub>10</sub> CFU/mL) | <b>−0.07</b>           | <b>0.01</b>    | <b>1.65 E<sup>−5</sup></b> |
| Study arm: single dose AmBisome                   | Odds ratio 1.03        | 0.08           | .71                        |
| Plasma PC1  | 0.00                   | 0.01           | .93                        |
| Plasma PC2  | −0.01                  | 0.01           | .67                        |
| Plasma PC3  | −0.02                  | 0.02           | .19                        |
| CSF PC1   | −0.01                  | 0.01           | .33                        |
| CSF PC2   | 0.00                   | 0.01           | .83                        |
| CSF PC3   | −0.01                  | 0.01           | .61                        |
| Amphotericin AUC <sub>0–24</sub> (g.L/h)          | <b>−0.14</b>           | <b>0.04</b>    | <b>.04</b>                 |
| Flucytosine AUC <sub>144–168</sub> (g.L/h)        | −0.04                  | 0.02           | .11                        |
| Fluconazole AUC <sub>144–168</sub> (g.L/h)        | 0.01                   | 0.01           | .29                        |

Bold values indicate statistically significant associations. EFA measured in log<sub>10</sub> CFU/mL/day.

Abbreviations: AUC, area under the concentration–time curve; CFU, colony forming unit; PC, principal component.

between amphotericin B formulations [14]. We did not design this study to detect those differences and indeed did not observe differences in these key inflammatory cytokines between study arms.

The immune response to HIV-associated cryptococcal meningitis is marked by significant interindividual heterogeneity. Identifying safe, generalizable targets for immunomodulatory therapy is hugely challenging. A randomized controlled trial of adjunctive IFN- $\gamma$  alongside amphotericin B deoxycholate and flucytosine demonstrated improved EFA and a trend toward reduced mortality in the IFN- $\gamma$  groups [7]. However, this intervention is not in routine clinical use, in large part because of a lack of robust evidence of mortality benefit. Larger trials of adjunctive IFN- $\gamma$  alongside a backbone of gold-standard antifungal treatment, including mortality endpoints, are required to explore this further. More data are also required to identify those who are most likely to benefit from adjunctive IFN- $\gamma$ . It is not clear, for example, whether ART status would alter the response to immunomodulation.

From the point of diagnosis of cryptococcal meningitis, the key intervention to improve outcomes remains the administration of potent antifungal therapy. Our analyses in CSF suggest a consistent immune signature that distinguishes between patients with high- and low-baseline fungal burden, high and low lumbar opening pressure, and mortality but fails to distinguish between high and low EFA. A plausible explanation for this is that antifungal drug exposure is more predictive of EFA than the immune response in the CNS. This hypothesis is supported by our multivariable analysis, with amphotericin B exposure remaining a significant predictor of EFA when adjusting

for baseline fungal burden, immune signatures, and exposure to fluconazole and flucytosine. We recently examined the relative contribution of pathogen genomics and antifungal pharmacokinetics to EFA in patients with HIV-associated cryptococcal meningitis and similarly concluded that the most significant contributor is exposure to amphotericin B [18].

This study has limitations. First, our cohort was relatively small in comparison to the number of clinical variables collected. We mitigated the statistical impact of this to a degree by implementing PCA and network analyses before undertaking regression analyses. Second, our estimates of amphotericin B exposure in CSF were derived from plasma samples. This is because measured levels of amphotericin B are negligible in CSF and the PK profile obtained from those samples is thought unlikely to reflect exposure in brain parenchyma [37, 38]. Our practice is therefore to measure in plasma and model CNS exposure. Third, we were unable to account for microbiological features such as strain lineage and phenotype in our analysis because our sample size was insufficient to support the addition of further datapoints. These data are published elsewhere [18].

In summary, our analysis supports an association between an inflammatory, Th-1 type immune response in the CSF and favorable clinical outcomes from HIV-associated cryptococcal meningitis. Our data emphasize the complexity of the immune response to HIV-associated cryptococcal meningitis and provide insight into the challenges of designing host-directed therapies. Furthermore, our data suggest that the impact of exposure to amphotericin B overshadows the impact of immune signatures either peripherally, or at the site of infection, on EFA. In the design of future treatment protocols for HIV-associated cryptococcal meningitis, optimized antifungal drug exposure should be an absolute priority. Access to potent anticytotoxic drugs is essential for all people who suffer with this disease.

## Supplementary Data

**Supplementary materials** are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

## Acknowledgments

We are indebted to the patients who participated in this study. In addition to the named authors, the following were members of the Ambition Study Group: Malawi-Liverpool-Wellcome Trust Clinical Research Programme/Queen Elizabeth Central Hospital, Blantyre, Malawi—T Chiphambano, E Dziwani, A Kadzimbile, S Kateta, E Kossam, C Kukacha, B Lipenga, J Ndaferankhande, M Ndalama, R Shah, A Singini, and A Zambasa. Botswana Harvard AIDS Institute Partnership/Princess Marina Hospital, Gaborone, Botswana—J Goodall, K Lechiile, N Mawoko, T Mbangiwa, J Milburn, R Mmipi, C Muthoga, P Ponatshego, I Rulaganyang, K Seatla, N Tlhako, and K Tsholo. University of Cape Town/Mitchells Plain Hospital/Khayelitsha District Hospital, Cape Town, South Africa—S April, A Bekiswa, L Boloko, H Bookholane, T Crede, L Davids, R Goliath, S Hlungulu, R Hoffman, H Kyepa, N Masina, D Maughan, T Mnguni, S Moosa, T Morar, M Mpalali, J Naude,

I Oliphant, S Sayed, L Sebesho, M Shey, and L Swanepoel. UNC Project, Kamuzu Central Hospital, Lilongwe, Malawi—T Banda, T Chikaonda, G Chitulo, L Chiwoko, N Chome, M Gwin, T Kachitosi, B Kamanga, M Kazembe, E Kumwenda, M Kumwenda, C Maya, W Mhango, C Mphande, L Msumba, T Munthali, D Ngoma, S Nicholas, L Simwinga, A Stambuli, G Tegha, and J Zambezi. Infectious Diseases Institute/Kiruddu General Hospital, Kampala, Uganda—C Ahimbisibwe, A Akampurira, A Alice, F Cresswell, J Gakuru, D Kiiza, J Kisembo, R Kwizera, F Kugonza, E Laker, T Luggya, A Lule, A Musubire, R Muyise, O Namujju, J Ndyetukira, L Nsangi, M Okirwoth, A Sadiq, K Tadeo, A Tukundane, and D Williams. Infectious Diseases Institute/Mbarara Regional Referral Hospital, Mbarara, Uganda—L Atwine, P Buzaare, M Collins, N Emily, C Inyakuwa, S Kariisa, J Mwesigye, S Niwamanya, A Rodgers, J Rukundo, I Rwomushana, M Ssemusu, and G Stead. University of Zimbabwe/Parirenyatwa General Hospital, Harare, Zimbabwe—K Boyd, S Gondo, P Kufa, E Makaha, C Moyo, T Mtisi, S Mudzingwa, T Mwarumba, and T Zinyandu. Institut Pasteur, Paris, France—A Alanio, F Dromer, and A Sturny-Leclerc. London School of Hygiene and Tropical Medicine, London, UK—P Griffin and S Hafeez.

**Author contributions:** K.E.S.: conceptualization, study design, sample analysis, data analysis, manuscript preparation, manuscript editing; D.T., C.K., A.A., D.N.: sample analysis; R.K.-D.: manuscript editing; C.S.: data analysis; M.M., E.G., W.C., M.C., R.V.S.: clinical study conduct; D.S.L.: clinical study conduct, manuscript editing; T.S.H., J.J.: principal investigators of AMBITION-cm, manuscript editing; D.G.L., W.H., H.C.M.: conceptualization, manuscript editing. All authors approved the submitted version of the manuscript.

**Financial support.** K.E.S. was funded by a Wellcome Trust Clinical Ph.D. Fellowship (203919/Z/16/Z) for the duration of the clinical study. K.E.S. currently holds a National Institute for Health Research Academic Clinical Lectureship. D.S.L. receives salary funding from the National Institute for Health Research (NIHR134342) using UK aid from the UK Government to support global health research. J.N.J. is supported by a grant (TRIA2015-1092) through the European and Developing Countries Clinical Trials Partnership, with assistance from the Swedish International Development Cooperation Agency, as well as by funding from the U.K. Department of Health and Social Care, the U.K. Foreign Commonwealth and Development Office, the U.K. Medical Research Council, and Wellcome Trust, through the Joint Global Health Trials scheme (MR/P006922/1). Financial support was also provided by the National Institute for Health Research through a Global Health Research Professorship (RP-2017-08-ST2-012, to J.N.J. and a Global Health Research Group [NIHR134342] providing salary support to D.S.L., T.S.H., and J.N.J.) with aid from the U.K. government to support global health research. The views expressed in this article are those of the authors and not necessarily those of the U.K. Department of Health and Social Care or the U.K. Foreign Commonwealth and Development Office.

**Potential conflicts of interest.** We declare no conflicts of interest.

## References

1. Jarvis JN, Lawrence DS, Mehta DB, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis. *N Engl J Med* 2022; 386:1109–20.
2. Molloy SF, Kanyama C, Heyderman RS, et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa. *N Engl J Med* 2018; 378:1004–17.
3. Coelho C, Bocca AL, Casadevall A. The intracellular life of *Cryptococcus neoformans*. *Annu Rev Pathol* 2014; 9:219–38.
4. Zaragoza O, Chrisman CJ, Castelli MV, et al. Capsule enlargement in *Cryptococcus neoformans* confers resistance to oxidative stress suggesting a mechanism for intracellular survival. *Cell Microbiol* 2008; 10:2043–57.
5. Tucker SC, Casadevall A. Replication of *Cryptococcus neoformans* in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. *Proc Natl Acad Sci U S A* 2002; 99:3165–70.
6. Scriven JE, Graham LM, Schutz C, et al. A glucuronoxylomannan-associated immune signature, characterized by monocyte deactivation and an increased interleukin 10 level, is a predictor of death in cryptococcal meningitis. *J Infect Dis* 2016; 213:1725–34.

7. Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. *AIDS* **2012**; 26:1105–13.
8. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. *J Immunol* **2005**; 174:1746–50.
9. Scriven JE, Graham LM, Schutz C, et al. The CSF immune response in HIV-1-associated cryptococcal meningitis: macrophage activation, correlates of disease severity, and effect of antiretroviral therapy. *J Acquir Immune Defic Syndr* **2017**; 75:299–307.
10. Mukaremera L, Nielsen K. Adaptive immunity to *Cryptococcus neoformans* infections. *J Fungi (Basel)* **2017**; 3:64.
11. Muller U, Stenzel W, Kohler G, et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with *Cryptococcus neoformans*. *J Immunol* **2007**; 179:5367–77.
12. Kawakami K, Kohno S, Kadota J, et al. T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed *Cryptococcus neoformans*: involvement of IFN-gamma and its protective effect against cryptococcal infection. *Microbiol Immunol* **1995**; 39: 135–43.
13. Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. *PLoS Pathog* **2015**; 11:e1004754.
14. Mesa-Arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. *Front Microbiol* **2012**; 3:286.
15. Ami RB, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. *Clin Infect Dis* **2008**; 47:226–35.
16. Stott KE, Ahmadu A, Kajanga C, et al. Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. *J Antimicrob Chemother* **2023**; 78:1015–22.
17. Stott KE, Moyo M, Ahmadu A, et al. Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. *J Antimicrob Chemother* **2022**; 78:276–83.
18. Stott KE, Mohabir JT, Bowers K, et al. Integration of genomic and pharmacokinetic data to predict clinical outcomes in HIV-associated cryptococcal meningitis. *mBio* **2024**; 15:e0159224.
19. Neely M, van Guilder M, Yamada W, Schumitzky A, Jelliffe R. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacokinetic modeling and simulation package for R. *Ther Drug Monit* **2012**; 34:467–76.
20. Jolliffe IT, Cadima J. Principal component analysis: a review and recent developments. *Philos Trans A Math Phys Eng Sci* **2016**; 374:20150202.
21. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis* **2014**; 58:736–45.
22. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. *Clin Infect Dis* **2009**; 49:702–9.
23. Decken K, Kohler G, Palmer-Lehmann K, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with *Cryptococcus neoformans*. *Infect Immun* **1998**; 66:4994–5000.
24. Okafor EC, Mukaremera L, Hullsiek KH, et al. CSF cytokines and chemokines involved in cytotoxic cell function and risk of acute 14-day mortality in persons with advanced HIV and cryptococcal meningitis. *J Infect Dis* **2025**; 231:521–31.
25. Havell EA. Production of tumor necrosis factor during murine listeriosis. *J Immunol* **1987**; 139:4225–31.
26. Nakano Y, Onozuka K, Terada Y, Shinomiya H, Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. *J Immunol* **1990**; 144:1935–41.
27. Denis M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. *J Leukoc Biol* **1991**; 50:495–501.
28. Steinsham S, Waage A. Tumor necrosis factor and interleukin-6 in *Candida albicans* infection in normal and granulocytopenic mice. *Infect Immun* **1992**; 60: 4003–8.
29. Laudanna C, Miron S, Berton G, Rossi F. Tumor necrosis factor-alpha/cachectin activates the O2(-)-generating system of human neutrophils independently of the hydrolysis of phosphoinositides and the release of arachidonic acid. *Biochem Biophys Res Commun* **1990**; 166:308–15.
30. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. *J Infect Dis* **2004**; 189:2185–91.
31. Graybill JR, Bocanegra R, Lambros C, Luther MF. Granulocyte colony stimulating factor therapy of experimental cryptococcal meningitis. *J Med Vet Mycol* **1997**; 35:243–7.
32. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. *J Infect Dis* **1991**; 163:579–83.
33. Chiller T, Farrokhsad K, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against *Cryptococcus neoformans*. *Med Mycol* **2002**; 40:21–6.
34. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. *J Exp Med* **1995**; 181:1519–26.
35. Bhatia SK, Tygrett LT, Grabstein KH, Waldschmidt TJ. The effect of in vivo IL-7 deprivation on T cell maturation. *J Exp Med* **1995**; 181:1399–409.
36. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? *Trends Immunol* **2001**; 22:564–71.
37. Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. *J Antimicrob Chemother* **2006**; 57:1153–60.
38. Strenger V, Meinitzer A, Donnerer J, et al. Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B. *J Antimicrob Chemother* **2014**; 69:2522–6.